Ekso Bionics Holdings, Inc. — Q2 2016 Form 10-Q
Entity and period: The filing identifies the registrant as Ekso Bionics Holdings, Inc. (not Chronoscale Holdings Corp.). It reports the quarter and six months ended June 30, 2016; financial amounts below are in thousands of dollars unless noted.
Business context and key financial metrics
The company develops and sells exoskeletons for medical, industrial, military and other uses. Its reportable segments are Medical Devices and Engineering Services.
| Metric | Q2 2016 | Q2 2015 | Six months 2016 | Six months 2015 |
|---|---|---|---|---|
| Revenue | $1,552 | $2,114 | $10,038 | $3,803 |
| Gross profit (margin) | $203 (13.1%) | $502 (23.7%) | $1,701 (16.9%) | $905 (23.8%) |
| Operating expenses | $7,599 | $6,137 | $15,739 | $10,633 |
| Operating loss | $(7,396) | $(5,635) | $(14,038) | $(9,728) |
| Net loss | $(5,765) | $(5,645) | $(9,416) | $(9,760) |
| Net loss applicable to common shareholders | $(9,970) | $(5,645) | $(16,745) | $(9,760) |
| Operating cash flow | Not stated separately | Not stated separately | $(14,122) | $(8,462) |
At June 30, cash was $4,661, down from $19,552 at December 31, 2015. Current assets were $9,367 and current liabilities $5,792; working capital was $3,575. Total assets were $13,575, total liabilities $12,014, and stockholders’ equity $1,561. The company reported $100,806 of accumulated deficit. Balance-sheet capital lease obligations were $78 current; other non-current liabilities were $162. Contractual commitments listed $1,102 in total, including leases, a leasehold-improvement loan and the Equipois supply agreement.
Material changes versus prior comparable periods
- Q2 revenue fell 27% year over year: medical-device revenue rose 38% to $1,451, but engineering-services revenue declined 91% to $101. Management attributed the engineering decline to shifting engineering resources toward internal product development.
- Six-month revenue rose 164%, largely reflecting a January 2016 change in revenue recognition. The company recognized $6,517 of previously deferred medical-device revenue and $4,159 of associated cost, adding $2,358 to gross profit. This materially affects comparison with 2015 and is not equivalent to current-period sales growth.
- For the six months, operating expenses increased 48%, led by higher sales and marketing, R&D and general and administrative costs. Operating loss widened 44%.
- Six-month net loss improved slightly, partly because of a $4,650 non-cash gain from revaluing warrants. Q2 net loss was similar to the prior year, but common-shareholder loss increased due to non-cash preferred deemed dividends of $4,205 in Q2 and $7,329 for the six months.
- Cash used in operations increased to $14,122 from $8,462. Management cited higher operating expenses, a one-time inventory build and investment in inventory expected to reverse over coming quarters.
Outlook, management commentary, risks and unusual items
- Liquidity and financing: Management said cash resources were sufficient to meet obligations only into September 2016 and that significant additional financing was required. It planned to pursue equity or debt financing, collaborations or warrant solicitations; no assurance was given that financing would be available on acceptable terms. Failure to obtain funding could require substantial expense reductions or curtailment of operations.
- Commercial and clinical plans: Following FDA clearance in April for the Ekso GT for specified stroke and spinal-cord-injury uses, the company said it was expanding U.S. and European marketing and sales efforts. It initiated the WISE clinical trial, targeting approximately 160 participants with chronic incomplete spinal cord injury, and was designing a global-use registry study. No financial guidance was provided.
- Regulatory: On July 19, 2016, after the quarter, the FDA expanded/clarified stroke labeling to include patients with upper-extremity function of at least 4/5 in only one arm. The FDA accepted corrective actions for four 2015 inspection observations in March 2016. The company reported seven device events subject to FDA reporting since July 2015, with no reported patient injuries, and said it had made design and manufacturing changes.
- Unusual accounting and costs: The revenue-recognition change released deferred revenue and costs from prior device shipments. The company also recorded a $911 one-time charge for preventative maintenance and upgrades to pre-2016 devices, and $212 of warranty expense. The warrant revaluation gain and preferred deemed dividends were non-cash.
- Other risks: The company cited dependence on additional capital, uncertain adoption and sales cycles, regulatory and clinical outcomes, competition, reimbursement, intellectual-property protection, foreign-exchange exposure and customer concentration. Five customers each represented at least 10% of Q2 billed revenue.
Important facts for investors to verify
- Confirm the registrant identity: this filing is for Ekso Bionics Holdings, Inc., despite the request metadata naming Chronoscale Holdings Corp.
- Assess actual cash burn and financing raised after the stated September 2016 liquidity horizon, including dilution or other financing terms.
- Separate recurring device revenue and margins from the $6,517 release of previously deferred revenue; track subsequent sales, service costs and maintenance liabilities.
- Review operating-expense trajectory, inventory conversion and whether management’s expectation that part of the inventory investment would reverse was realized.
- Monitor FDA labeling, clinical-trial progress, reported device events and the company’s ability to translate clearance and marketing efforts into sustained commercial demand.